Today we submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (@EMA_News) for our oral somatostatin analog for people living with #acromegaly. Click here to read the full press release: https://t.co/nuco6WE8dH $CHMA
One year ago today, our first and only oral therapy for #acromegaly was approved by the @US_FDA! We are inspired every day to team up with healthcare providers to deliver it to patients in need.
#EmployeeHighlight: Meet Lucie Bayer, Director, Patient Marketing. At Chiasma, she channels and amplifies the patient voices her team serves, working with passion to understand the needs and expectations of people living with #acromegaly.
We are passionate about our purpose, we are committed to each other and we act as one #team with a heightened sense of urgency. Learn more about us here: https://t.co/Mlx3JE7wh6
We believe that patients with #RareDiseases deserve treatment options that can improve their outcomes and quality of life. Learn more about our work: https://t.co/4c19iydTZA
At Chiasma, people are at the center of everything we do. To find trusted resources and connect with patient advocacy groups that support the #acromegaly community, click here: https://t.co/fOMASM3RvS
As the world begins to re-open, our CEO, Raj Kannan, shares his thoughts on remote working and going back to the office #post-pandemic. Click here to learn more: https://t.co/QqpyFwb90K
#EmployeeHighlight: Meet Toby Damron, PharmD, RPh, Director, Medical Science Liaison at Chiasma. Toby works w/ leading #endocrinologists & experts in the field of #acromegaly to help improve the lives of #patients. Learn more about our team’s mission here: https://t.co/NeSfrNvJSu
Congratulations to #eECE 2021 presenting author Dr. Nienke Biermasz for winning a Top 8 e-Poster Award! Her e-Poster will be available on the e-ECE platform and on ESE On Demand for the next 60 days. To view her e-poster, register here: https://t.co/LxVwoIKvfX
Today at #AACE2021 (@TheAACE), we presented new findings from our MPOWERED™ Phase 3 #ClinicalTrial. Read the full press release for more information here: https://t.co/blXNPwjHKK
Visit our product theatre at #AACE2021 (@TheAACE) to hear Dr. Anthony P. Heaney discuss results from our Phase 3 CHIASMA OPTIMAL study. Register here: https://t.co/M5ff00p72N
Congratulations to #eECE2021 presenting author Dr. Nienke Biermasz who is nominated for a Top 20 e-Poster award! Register for her session highlighting encore data from our MPOWERED™ Phase 3 #ClinicalTrial: https://t.co/iAMox01DRr
We’re presenting data from our MPOWERED™ Phase 3 #ClinicalTrial at the 23rd European Congress of Endocrinology (@ESEndocrinology). To view our posters and oral presentation, register here: https://t.co/iAMox01DRr #eECE2021
Check out this @biospace article featuring our CEO Raj Kannan who, along with other #biopharma leaders, addresses the challenges of the post-pandemic workplace. Read the full article here: https://t.co/ch7wep17S7
We’re virtually presenting encore and new data from our MPOWERED™ Phase 3 #ClinicalTrial at #eECE2021 (@ESEndocrinology), held May 22-26 2021, and #AACE2021 (@TheAACE), held May 26-29, 2021. Learn more: https://t.co/BFTeF2deno
#EmployeeHighlight: Meet Jason Crompton, our Head of Scientific Communications. Jason loves synthesizing complex information into clear points for patients and health care providers. Find out more about open positions on our team: https://t.co/21z44TsqWZ
Our CEO, Raj Kannan, will participate in a @biospace panel discussion, titled “The Future of BioPharma: Laying the Groundwork for a Post-Pandemic Workplace” today at 2:00 pm EST. Click here to register: https://t.co/NiN9M1dXUP
The 7th Annual Customer Centric Medical Information Conference is taking place March 30-April 1 virtually. Register here for more from Chiasma's VP of Medical Affairs, Scott McConnell, and Medical Information Manager, Jordan Paavola: https://t.co/dIeT9aFTSc #Q1MEDINFO
Today at #ENDO21 (@TheEndoSociety), we announced new findings from the open label extension (OLE) of the Chiasma OPTIMAL Phase 3 study. Read the full press release for more information: https://t.co/40UPQaYQUp